Table 5.
Melanomas with coexisting mutations in 31 melanomasa
| BRAF | HRAS | KRAS | NRAS | PIK3CA | KIT | CM (%)b | |
|---|---|---|---|---|---|---|---|
| BRAF | 1c | 3 | 1 | 4 | 5 | 5 | 18 (10%) |
| HRAS | 3 | 0 | 1 | 0 | 1 | 1 | 6 (67%) |
| KRAS | 1 | 1 | 0 | 1 | 0 | 0 | 3 (25%) |
| NRAS | 4 | 0 | 1 | 2d | 2 | 1 | 9 (8.1%) |
| PIK3CA | 5 | 1 | 0 | 2 | 1 | 1 | 9 (75%) |
| KIT | 5 | 1 | 0 | 1 | 1 | 2e | 8 (36%) |
aIncluding 29 tumors with 2 mutations and 2 tumors with 3 mutations
bCoexisting mutation (CM) within different genes
cp.S605I with unknown kinase activity and p.V600E within the same allele
dOne with NRAS p.Q61L and p.Y64D of unknown activating status, and one with NRAS p.G13D, p.Q61K and PIK3CA p.E542G
eOne with p.V560A and p.N822Y, and one with p.P573S, p.F681I and p.N822I